Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy

NCT ID: NCT03080116

Last Updated: 2024-07-03

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-03-28
• Study Completion Date: 2024-07-01

Brief Summary

RATIONALE: Neoadjuvant hormonal therapy using luteinizing hormone releasing hormone (LHRH) agonists and/or anti-androgens has already demonstrated to downstage primary prostate cancer in patients treated by radical prostatectomy without a survival benefit. There is no evidence yet of a survival impact of LHRH antagonist (LHRHa) +/- new-generation anti-androgens in this setting. Thus novel studies are needed to assess this treatment combination.

PURPOSE: To assess the difference in treatment antitumor effect between arms by measuring pathological tumor volume with minimal residual disease (MRD) following radical prostatectomy + pelvic lymph-node dissection (RP + PLND) for intermediate or high-risk prostate cancer patients.

Detailed Description

PRIMARY OBJECTIVE: To assess the difference in antitumor effect between the treatment arms by measuring MRD following radical prostatectomy.

SECONDARY OBJECTIVES: To measure differences between study arms in

• Proportions of post neoadjuvant prostate specific antigen (PSA) ≤ 0.3 ng/ml as a predictor of prostate cancer mortality
• T down-staging, complete pathological response, PSA kinetics, Testosterone kinetics, operation time, blood loss, grade of surgical difficulty
• New generation hybrid imaging 68Ga PSMA (Prostate-Specific Membrane Antigen) PET/MR (Positron emission tomography/Magnetic Resonance) derived parameters
• Early biochemical recurrence as prognostic factor of prostate cancer mortality
• Transcriptome and genome
• Tissue microarrays (TMA) protein expression (DNA repair, resistance etc.) by immunohistochemistry
• Perioperative safety and tolerability
• Quality of life, erection recovery, continence through validated preoperative and postoperative questionnaires pre and postop (IEEF5, ICIQ, EORTC QLQ-C30)

OUTLINE: interventional, single center, phase II, randomized, double blind, placebo controlled trial.

Conditions

Prostate Cancer; Neoadjuvant Therapy; Androgen Antagonists; Prostatectomy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

ARN-509 + degarelix

Treatment period of 12 weeks before RP + PLND.

Group Type: EXPERIMENTAL

ARN-509

Intervention Type: DRUG

240mg/day (4x60mg tablets, Oral administration: OS)

Degarelix

Intervention Type: DRUG

1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly

placebo + degarelix

Treatment period of 12 weeks before RP + PLND.

Group Type: ACTIVE_COMPARATOR

Degarelix

Intervention Type: DRUG

1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly

Placebo

Intervention Type: OTHER

4 tablets, per OS

Interventions

ARN-509

240mg/day (4x60mg tablets, Oral administration: OS)

Intervention Type: DRUG

Degarelix

1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly

Intervention Type: DRUG

Placebo

4 tablets, per OS

Intervention Type: OTHER

Other Intervention Names

apalutamide

Eligibility Criteria

Inclusion Criteria

1. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

2. Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations

3. Male aged 18 years or older (within 80 years)

4. Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features

5. Diagnosis of intermediate (at least 2 of the following factors: cT2b, biopsy GS 7, PSA 10-20ng/ml) or high-risk prostatic adenocarcinoma (clinical stage≥T2c and/or biopsy GS≥8 and/or PSA>20ng/ml), cN0-cN1, cM0.

6. Patient amenable for open or robotic radical prostatectomy + pelvic lymph node dissection

7. ECOG performance status: 0-1

8. Adequate organ function as defined by the following criteria:

• White blood cells (WBC) ≥ 4.0 x109/L
• Platelet count ≥ 100 x109/L
• Hemoglobin ≥9 g/dl
• Creatinine ≤ 2 x ULN
• Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 x upper limit of normality (ULN)
• Total serum bilirubin ≤1.5 x ULN.

Exclusion Criteria

1. Previous surgical/endoscopic treatments for prostatic disease

2. Herbal and non-herbal products that in the opinion of the investigator may decrease PSA levels

3. cM1 disease

4. Any contraindication for PET or MR investigations

5. History of seizure or condition that may pre-dispose to seizure (e.g., prior stroke within 1 year prior to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy)

6. Medications known to lower the seizure threshold

7. History of:

• Any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer currently in complete remission) within 5 years prior to randomization
• Severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization
• Uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic BP ≥100 mmHg). Patients with a history of uncontrolled hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment.
• Gastrointestinal disorder affecting absorption

8. Any other condition that, in the opinion of the Investigator, would impair the patient's ability to comply with study procedures.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Universitaire Ziekenhuizen KU Leuven

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Steven Joniau

Role: PRINCIPAL_INVESTIGATOR

UZ Leuven

Locations

University Hospitals Leuven

Leuven, Vlaams-brabant, Belgium

Countries

Belgium

References

Tosco L, Laenen A, Gevaert T, Salmon I, Decaestecker C, Davicioni E, Buerki C, Claessens F, Swinnen J, Goffin K, Oyen R, Everaerts W, Moris L, De Meerleer G, Haustermans K, Joniau S; P.E.A.R.L. (ProstatE cAncer Research Leuven). Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. BMC Cancer. 2018 Apr 2;18(1):354. doi: 10.1186/s12885-018-4275-z.

Reference Type: DERIVED

PMID: 29606109 (View on PubMed)

Other Identifiers

2016-002854-19

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

S58827

Identifier Type: -

Identifier Source: org_study_id